Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction
This study is looking at how a natural substance called resveratrol might help people with type 1 diabetes. Researchers want to see if taking 500 mg of oral trans-resveratrol twice a day for 12 weeks can improve how your body's endothelin-B receptor (a protein involved in blood vessel function) works and also improve the function of your muscle cells' powerhouses (mitochondria). They believe that increasing a protein called Sirtuin-1 with resveratrol could lead to these improvements. You may be able to join if you are an adult man or premenopausal woman with type 1 diabetes, and do not have certain other health conditions. The study aims to enroll 24 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive either resveratrol or a placebo. It plans to enroll 24 participants.
- What's involved
- Participants will take either resveratrol or a placebo twice daily for 12 weeks. Measurements will be taken at the beginning and after 12 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Measurements are taken at baseline and after 12 weeks of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in AUC for ET-1 + BQ-123Measure taken at Baseline and post 12 weeks
Change in Area Under the Curve (AUC) for Cutaneous Vascular Conductance (CVC) in response to co-perfusion of ET-1 + BQ-123 at 12 weeks. Measured using intradermal microdialysis technique in conjunction with Laser Speckle Contrast Imaging (Moor FLPI-2) and beat-by-beat blood pressure monitoring (Finapres NOVA).
- Skeletal Muscle Mitochondrial FunctionMeasure taken at Baseline and post 12 weeks
Change in Skeletal Muscle Mitochondrial Function at 12 weeks. Measured using Near Infrared Spectroscopy (NIRS). Values are an index of phosphocreatine recovery expressed as a rate constant (min-1)